Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Inclusion Criteria: * Mesothelioma that has been previously treated with at least one chemotherapy regimen * 18 years of age or older * Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities * Four or more weeks since last major surgery * Four or more weeks since last radiation therapy * Three or more weeks since last chemotherapy * Life expectancy of 12 weeks or more * Blood tests that show kidneys, liver and bone marrow to be working adequately * Able to comply with study and/or follow-up procedures Exclusion Criteria: * Prior exposure to Tarceva (OSI-774, erlotinib), trastuzumab, ZD1839 or C225 * Receiving anticoagulation medication other than low dose Coumadin * Clinically significant heart disease such as uncontrolled hypertension, previous heart attack within past 12 months, uneven heartbeat, etc. * History of central nervous system disease such as seizures not controlled with standard medical therapy, brain metastases or history of stroke * Major surgery within 28 days of screening * Daily treatment with aspirin or anti-inflammatory medications * Pregnant or lactating (pertaining to women only) * Serious or nonhealing wound, ulcer or bone fracture * Difficulty swallowing * A disease or disorder that interferes with ability to digest and absorb food * History of coughing up more than 1/4 teaspoon of blood * A medical condition that could make it unsafe for patient to participate in this study